January 24, 2022
Using national TV, radio, and web media campaigns, Microgen Diagnostics will be the first independent commercial lab in the U.S. to appeal directly to patients, raising awareness about much more effective DNA analysis alternatives to outdated medical diagnostic technologies like standard culture. The campaign, scheduled for February of 2022, includes testimonials from patients about how MicroGenDX diagnostics helped them – and in some cases saved their lives – when standard cultures failed.
December 14, 2021
Clinical research using MicroGenDX molecular testing highlights diagnostic applications
October 8, 2021
Dr. Karan Goswami of the Rothman Orthopaedic Institute at Thomas Jefferson University has received the prestigious Eastern Orthopaedic Association’s Parvizi Musculoskeletal Infection Award for his paper entitled “Fracture-associated Microbiome and Persistent Nonunion: Next-Generation Sequencing Reveals.” This award is given to a Resident or Fellow with one of the top papers presented at the EOA’s Annual Meeting.
September 16, 2021
Dr. J. Curtis Nickel, with the help of MicroGenDX, has completed a study to help understand the implications of Next-Generation DNA Sequencing (NGS) in the diagnosis and treatment of Urinary Tract Infections (UTIs) and other inflammatory urological conditions.
September 10, 2021
ORLANDO, Fla., May 24, 2021 /PRNewswire/ — MicroGen Diagnostics (MicroGenDX) is pleased to announce that it has resolved a dispute with AdventHealth concerning Covid-19 testing services that were provided to AdventHealth during the height of the global pandemic in May of 2020.